The autoimmune drug market is dominated by blockbuster biologics, including Janssen’s Stelara® (ustekinumab), a dual IL-23 and IL-12 inhibitor approved for plaque psoriasis, psoriatic arthritis, Crohn’s disease and ulcerative colitis. These biologics generate billions in annual revenue, but when exclusivity ends, competition from biosimilars quickly becomes a concern.

Using the real-world example of Stelara, which faced multiple new biosimilars within a year of its patent expiry, we explore how to sustain value with smarter lifecycle strategy. We’ll combine data curation, large-scale ‘omics evidence and pathway analytics with QIAGEN Discovery Platform to uncover new opportunities for Stelara.

In this session, you’ll learn how to:

• Support discovery decisions in immunology research

• Contextualize targets with curated biological knowledge and pathway analytics

• Identify opportunities for indication expansion and combination strategies

• Generate AI-ready insights from integrated multimodal data and knowledge graphs

Speakers:

Tim Hou, PhD

Senior Field Application Scientist, QIAGEN Digital Insights

Tim Hou, PhD, is a Senior Field Application Scientist at QIAGEN Digital Insights, where he leverages extensive expertise in molecular biology, genomics and bioinformatics to support researchers with biological data analysis and interpretation platforms from QIAGEN.

Ethan Strattan, PhD

Immunology Consulting Scientist, QIAGEN Digital Insights

Ethan Strattan, PhD, helps clients understand the biological underpinnings of ‘omics-level findings. He works as an immunology and oncology subject matter expert in the QDI Services team, bridging the gap between data scientists and bench researchers. He works with diverse datasets to generate use cases and proof-of-concepts for findings generated from cutting-edge informatics and AI pipelines.